Ramucirumab + Paclitaxel

DRUG2 trials

Sponsors

ALX Oncology Inc., Gruppo Oncologico del Nord-Ovest

Conditions

Advanced CancerGastroesophageal AdenocarcinomaMetastatic CancerNonHodgkin LymphomaSolid Tumor

Phase 1

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

CompletedNCT03013218

ALX Oncology Inc.Metastatic Cancer, Solid Tumor, Advanced Cancer +1

Start: 2017-02-03End: 2025-07-08Updated: 2025-08-01

Phase 3

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

Not yet recruitingNCT07763171

Gruppo Oncologico del Nord-OvestGastroesophageal Adenocarcinoma

Start: 2026-09-01End: 2031-09-01Target: 244Updated: 2026-08-18

Related Papers

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study

Haematologica2025-04-104 citations

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

2021-11-1594 citations

498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

Regular and Young Investigator Award Abstracts2021-11-018 citations

404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

Regular and Young Investigator Award Abstracts2020-11-011 citations

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.

Journal of Clinical Oncology2020-05-2019 citations

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Blood2019-11-1325 citations

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

Journal of Clinical Oncology2019-05-2018 citations

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

Journal of Clinical Oncology2018-05-2020 citations

ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models

Blood2017-12-078 citations